Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,225 shares of the biopharmaceutical company’s stock after purchasing an additional 31,109 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Gilead Sciences were worth $49,956,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. PFS Partners LLC grew its position in shares of Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $25,000. Laurel Wealth Advisors LLC acquired a new stake in Gilead Sciences in the third quarter valued at approximately $29,000. Kimelman & Baird LLC acquired a new stake in Gilead Sciences in the second quarter valued at approximately $25,000. Finally, Toth Financial Advisory Corp raised its holdings in Gilead Sciences by 85.5% in the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,881 shares of company stock valued at $19,252,455 over the last three months. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on GILD shares. BMO Capital Markets reiterated an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research note on Friday. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. UBS Group raised their price objective on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a report on Friday. Finally, Jefferies Financial Group set a $196.00 price objective on shares of Gilead Sciences in a research report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $170.15.

Gilead Sciences Trading Down 1.7%

GILD opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $175.65. The company has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. The business’s 50-day simple moving average is $151.77 and its 200-day simple moving average is $140.25.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the company earned $2.47 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.